| 1 |
Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma[J]. J Immunol, 1987, 138(3):989-995.
|
| 2 |
Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects[J]. Front Immunol, 2022, 13:835762.
|
| 3 |
Sano E, Kazaana A, Tadakuma H, et al. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119037.
|
| 4 |
Upadhyay R, Boiarsky JA, Pantsulaia G, et al. A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy[J]. Cancer Discov, 2021, 11(3):599-613.
|
| 5 |
Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries[J]. Cell Death Differ, 2023, 30(2):237-249.
|
| 6 |
Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma[J]. J Clin Oncol, 2005, 23(10):2346-2357.
|
| 7 |
Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients[J]. Clin Cancer Res, 2012, 18(24):6758-6770.
|
| 8 |
Hopewell EL, Cox C, Pilon-Thomas S, et al. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process[J]. Cytotherapy, 2019, 21(3):307-314.
|
| 9 |
Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study[J]. J Immunother Cancer, 2022,10(12):e005755.
|
| 10 |
Qu R, Kluger Y, Yang J, et al. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure[J]. Mol Cancer, 2022, 21(1):219.
|
| 11 |
Verma NK, Wong BHS, Poh ZS, et al. Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint[J]. EBioMedicine, 2022, 83:104216.
|
| 12 |
Jin Y, Dong Y, Zhang J, et al. The toxicity of cell therapy: mechanism, manifestations, and challenges[J]. J Appl Toxicol, 2021, 41(5):659-667.
|
| 13 |
Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy[J]. Clin Cancer Res, 2011, 17(13):4550-4557.
|
| 14 |
Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma[J]. N Engl J Med, 2022, 387(23):2113-2125.
|
| 15 |
Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating llymphocyte therapy, in metastatic melanoma[J]. J Clin Oncol, 2021, 39(24):2656-2666.
|
| 16 |
Medina T, Chesney JA, Kluger HM, et al. Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study[J]. J Clin Oncol, 2025, 2:101200JCO2500765.
|
| 17 |
Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8):1410-1418.
|
| 18 |
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184):641-645.
|
| 19 |
Tran E, Robbins PF, Lu YC, et al. T-Cell transfer therapy targeting mutant KRAS in cancer[J]. N Engl J Med, 2016, 375(23):2255-2262.
|
| 20 |
Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells[J]. J Clin Oncol, 2015, 33(14):1543-1550.
|
| 21 |
Stevanović S, Pasetto A, Helman SR, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer[J]. Science, 2017, 356(6334):200-205.
|
| 22 |
Stevanović S, Helman SR, Wunderlich JR, et al. A phase Ⅱ study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5):1486-1493.
|
| 23 |
Guo J, Wang C, Luo N, et al. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer[J]. BMC Med, 2024, 22(1):207.
|
| 24 |
Zacharakis N, Chinnasamy H, Black M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer[J]. Nat Med, 2018, 24(6):724-730.
|
| 25 |
Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase Ⅱ pilot clinical trial using mutation-reactive autologous lymphocytes[J]. J Clin Oncol, 2022, 40(16):1741-1754.
|
| 26 |
Lowery FJ, Goff SL, Gasmi B, et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial[J]. Nat Med. 2025, 31(6):1994-2003.
|
| 27 |
Wei L, Wang Z, Zhang Z, et al. Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia[J]. Cancer Manag Res, 2019, 11:3187-3196.
|
| 28 |
Cao H, Kim DH, Howard A, et al. Ex vivo isolation, expansion and bioengineering of CCR7+ CD95-/or CD62L+ CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow[J]. Neoplasia, 2021, 23(12):1252-1260.
|
| 29 |
Zamora AE, Crawford JC, Allen EK, et al. Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses[J]. Sci Transl Med, 2019, 11(498):eaat8549.
|
| 30 |
Apollonio B, Spada F, Petrov N, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma[J]. J Clin Invest, 2023, 133(13):e166070.
|
| 31 |
高全立, 韩露, 徐本玲, 等. 应用肿瘤浸润淋巴细胞治疗难治复发B细胞淋巴瘤3例报告[C]. 第十四届全国肿瘤生物治疗大会论文集, 2015.
|
| 32 |
Menguy S, Prochazkova-Carlotti M, Azzi-Martin L, et al. Proliferative tumor-infiltrating llymphocytes' abundance within the microenvironment impacts clinical outcome in cutaneous B-Cell lymphomas[J]. J Invest Dermatol, 2023, 143(1):124-133.e3.
|
| 33 |
Oliveira G, Stromhaug K, Klaeger S, et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma[J]. Nature, 2021, 596(7870):119-125.
|
| 34 |
Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma[J]. Clin Cancer Res, 2021, 27(19):5289-5298.
|
| 35 |
Lowery FJ, Krishna S, Yossef R, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers[J]. Science, 2022, 375(6583):877-884.
|
| 36 |
Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor[J]. Clin Cancer Res, 2014, 20(1):44-55.
|
| 37 |
Bernatchez C, Balasubramanian P, Cressman EN, et al. Minimally invasive tumor tissue procurement is feasible for clinical manufacturing of OBX-115 engineered tumor-infiltrating lymphocytes(TIL)[J]. Cytotherapy, 2024, 26(6):S154-155.
|
| 38 |
Katti A, Diaz BJ, Caragine CM, et al. CRISPR in cancer biology and therapy[J]. Nat Rev Cancer, 2022, 22(5):259-279.
|
| 39 |
Lipp JJ, Wang L, Yang H, et al. Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients[J]. Oncoimmunology, 2022, 11(1):2019466.
|
| 40 |
Lou E, Choudhry MS, Starr TK, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial[J]. Lancet Oncol, 2025, 26(5):559-570.
|
| 41 |
Schlabach MR, Lin S, Collester ZR, et al. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens[J]. J Clin Invest, 2023, 133(24):e163096.
|
| 42 |
Chamberlain CA, Bennett EP, Kverneland AH, et al. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy[J]. Mol Ther Oncolytics, 2022, 24:417-428.
|
| 43 |
Kalaitsidou M, Moon OR, Sykorova M, et al. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes[J]. Front Immunol, 2023, 14:1256491.
|
| 44 |
Wen T, Barham W, Li Y, et al. NKG7 is a T-cell-Intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy[J]. Cancer Immunol Res, 2022, 10(2):162-181.
|
| 45 |
Srirat T, Hayakawa T, Mise-Omata S, et al. NR4a1/2 deletion promotes accumulation of TCF1+ stem-like precursors of exhausted CD8+ T cells in the tumor microenvironment[J]. Cell Rep, 2024, 43(3):113898.
|
| 46 |
Feng H, Qiu L, Shi Z, et al. Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy[J]. Cancer Med, 2023, 12(3):3313-3327.
|
| 47 |
Na K, Lee S, Kim DK, et al. CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production[J]. Front Immunol, 2024, 15:1336246.
|
| 48 |
Pesce E, Cordiglieri C, Bombaci M, et al. TMEM123 a key player in immune surveillance of colorectal cancer[J]. Front Immunol, 2023, 14:1194087.
|
| 49 |
Fix SM, Forget MA, Sakellariou-Thompson D, et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling[J]. J Immunother Cancer, 2022, 10(7):e003750.
|
| 50 |
Islam SMR, Maeda T, Tamaoki N, et al. Reprogramming of tumor-reactive tumor-infiltrating lymphocytes to human-induced pluripotent stem cells[J]. Cancer Res Commun, 2023, 3(5):917-932.
|
| 51 |
Wang C, Yu X, Teer JK, et al. Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy[J]. Nat Cancer, 2025, 6(5):801-819.
|
| 52 |
Yu Z, Guo Z, Jiang B, et al. IL-7-PD-L1 nano-antibody mediated "zipper" effect augments the tumoricidal activity of tumor-infiltrating lymphocytes[J]. Exp Hematol Oncol, 2025, 14(1):112.
|